ArticleBMC cancer2025

Protocol of the IMPACT study: randomized, multicenter, phase 3 study evaluating the efficacy of immunotherapy (Atezolizumab) plus anti-VEGF therapy (Bevacizumab) in combination with transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma.

Yoshihisa Kodama et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.